Get the Stockscreener App
4.55
4.41%
-0.21
After Hours:
4.57
0.02
+0.44%
Abeona Therapeutics Inc stock is traded at $4.55, with a volume of 2.85M.
It is down -4.41% in the last 24 hours and down -11.13% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$4.76
Open:
$4.67
24h Volume:
2.85M
Relative Volume:
2.37
Market Cap:
$246.57M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
4.5628
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
-9.18%
1M Performance:
-11.13%
6M Performance:
-19.33%
1Y Performance:
-11.82%
1-Day Range:
$4.36
$4.67
1-Week Range:
$4.36
$5.02
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.55 | 268.25M | 5.82M | 71.18M | -84.30M | 0.9972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative - simplywall.st
Abeona targets activation of 7 QTCs for ZEVASKYN by end of 2026 as patient demand doubles - MSN
Abeona Therapeutics Balances Big Windfall With Slow Ramp - TipRanks
Oppenheimer reiterates Abeona Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Stifel cuts Abeona Therapeutics stock price target on sales timing - Investing.com
Stifel cuts Abeona Therapeutics stock price target on sales timing By Investing.com - Investing.com UK
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: - GuruFocus
Abeona Therapeutics Reports 2025 Financial Results, ZEVASKYN Launch Momentum, and $191.4M Cash Position - Minichart
Abeona (ABEO) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
ABEO: Strong launch momentum, profitability, and expanding access position ZEVASKYN for growth - TradingView
Abeona (ABEO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Abeona Therapeutics Q4 Earnings Call Highlights - MarketBeat
ABEO: 2025 marked a profitable year with ZEVASKYN's launch, expanding access, and robust financials - TradingView
Earnings call transcript: Abeona Therapeutics Q4 2025 shows revenue growth - Investing.com
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Abeona Therapeutics 2025 Financial Results: Annual Profit and Q4 BeatNews and Statistics - IndexBox
Abeona Therapeutics (ABEO) Reports Mixed FY Results with Revenue Beat - GuruFocus
Abeona Therapeutics FY income from operations USD -89.448 million versus Ibes estimate USD -78.4 million - marketscreener.com
Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
ABEO Exceeds Revenue Expectations with Strong Biopsy and Treatme - GuruFocus
ABEONA THERAPEUTICS ($ABEO) Releases Q4 2025 Earnings - Quiver Quantitative
The latest financial data released by biotechnology company Abeona Therapeutics Inc shows its annual operating income recorded at -89.448 millions USD. - Bitget
Abeona Therapeutics: Fourth Quarter Earnings Overview - Bitget
Abeona Therapeutics 10-K: $5.82M Revenue, $71.18M Net Income - TradingView
Abeona Therapeutics: Q4 Earnings Snapshot - kens5.com
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates - The Manila Times
Abeona (NASDAQ: ABEO) shifts to commercial stage with ZEVASKYN and $155M PRV cash - Stock Titan
Abeona Therapeutics (Nasdaq: ABEO) turns 2025 profit on PRV sale and builds cash - Stock Titan
First ZEVASKYN patients treated as Abeona banks $191M cash - Stock Titan
Earnings Scheduled For March 17, 2026 - Benzinga
Abeona Therapeutics CFO Vazzano sells $3.7k in stock - Investing.com
ABEO (NASDAQ) Form 144: 2,000 RSUs listed; insider sold 18,666 shares - Stock Titan
Abeona (NASDAQ: ABEO) CFO sells 785 shares to cover tax obligations - Stock Titan
Published on: 2026-03-17 00:22:57 - baoquankhu1.vn
Abeona Therapeutics Inc. $ABEO Shares Sold by Boone Capital Management LLC - MarketBeat
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Understanding Momentum Shifts in (ABEO) - Stock Traders Daily
Abeona Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Abeona reports progress in ZEVASKYN gene therapy launch - Investing.com Nigeria
Q4 EPS Forecast for Abeona Therapeutics Increased by Analyst - MarketBeat
HC Wainwright Has Bullish Outlook for ABEO FY2025 Earnings - MarketBeat
Abeona Therapeutics (ABEO) Receives Consistent Analyst Rating of "Buy" | ABEO Stock News - GuruFocus
Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026 - MarketBeat
Abeona Therapeutics at Leerink Global Healthcare Conference: Strategic Launch Insights - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics (ABEO) Projected to Post Earnings on Tuesday - MarketBeat
Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026 - Meyka
Oppenheimer raises Abeona Therapeutics price target on launch progress By Investing.com - Investing.com Nigeria
Oppenheimer raises Abeona Therapeutics price target on launch progress - Investing.com
Why Is Abeona Therapeutics Inc. (ABEO) Stock Up Today? - Meyka
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):